Glypican 3 Protein (GPC3) (Fc Tag)

Produktnummer ABIN7092674

Produktdetails

Target: Glypican 3 (GPC3)

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses Glypican 3 Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Recombinant Human GPC3 Protein with N-terminal Human Fc tag

Spezifität: HFc (Glu99-Ala330) GPC3 (Asp511-Ser560)

Produktmerkmale: Extracellular Domain Protein

Aufreinigung: Purified from cell culture supernatant by affinity chromatography

Reinheit: The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Haltbarkeit: 12 months

Antigendetails

Target: Glypican 3 (GPC3)

Andere Bezeichnung: GPC3 (GPC3 Produkte)

Hintergrund: Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009] References: Fu Ying, Urban Daniel J, Nani Roger R et al. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.[J] .Hepatology, 2019, 70: 563-576. Zhang Yi-Fan, Ho Mitchell, Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.[J] .Sci Rep, 2016, 6: 33878.

Molekulargewicht: predicted molecular mass of 43.3 kDa after removal of the signal peptide.

UniProt: P51654

Pathways: Glycosaminoglycan Metabolic Process